Intra-discal Steroid Injection for MODIC I Discopathy
Summary
To assess the efficacy on pain level at 1 month and 12 months of a steroid injection in the inter-vertebral disc for patients with chronic back pain and inflammatory discopathy on magnetic resonance imaging. Hypothesis: delivering anti-inflammatory drugs in situ may decrease back pain in patients with inflammatory discopathy
Timeline
- Start
- 2009-04
- Primary completion
- 2015-05
- Completion
- 2015-11
Outcome
Met primary endpoint
paper At 1 month after the intervention, the percentage of responders (LBP intensity <40) was higher in the GC IDI group PMID 28319997 ↗
paper than the control group (21 of 63 [33.3%]) (absolute risk difference, 22.1 percentage points [95% CI, 5.5 to 38.7 percentage points]; P = 0.009). PMID 28319997 ↗
paper In chronic LBP associated with active discopathy, a single GC IDI reduces LBP at 1 month but not at 12 months. PMID 28319997 ↗
Publications
- Results Nguyen C, Boutron I, Baron G, Sanchez K, Palazzo C, Benchimol R, Paris G, James-Belin E, Lefevre-Colau MM, Beaudreuil J, Laredo JD, Bera-Louville A, Cotten A, Drape JL, Feydy A, Ravaud P, Rannou F, Poiraudeau S. Intradiscal Glucocorticoid Injection for Patients With Chronic Low Back Pain Associated With Active Discopathy: A Randomized Trial. Ann Intern Med. 2017 Apr 18;166(8):547-556. doi: 10.7326/M16-1700. Epub 2017 Mar 21.
- Daste C, Abdoul H, Foissac F, Lefevre-Colau MM, Poiraudeau S, Rannou F, Nguyen C. Patient acceptable symptom state for patient-reported outcomes in people with non-specific chronic low back pain. Ann Phys Rehabil Med. 2022 Jan;65(1):101451. doi: 10.1016/j.rehab.2020.10.005. Epub 2020 Nov 26.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrocortancyl | Other / unclassified | 25 mg | Other |
| Background | Iodixanol | Diagnostic / imaging agent | 1 ml | Other |
Indications
No indication recorded.